Psychiatrists gathered for the annual American Psychiatric Association meeting, with neuroscience taking a more visible role than in prior years. Traditional concerns remained, including heavily funded pharmaceutical exhibitions, political messaging, and speeches that often did not change outcomes for patients. The educational program shifted, featuring more than two dozen talks on neuromodulation and inviting leading experts in brain stimulation and advanced brain imaging. The exhibition hall also expanded beyond medications, highlighting neurotechnology for multiple conditions. FDA-cleared take-home brain stimulation devices were presented for depression, and additional technologies were described as being developed. Psychedelic therapies were also anticipated, with expectations of FDA clearance by the next meeting.
"What was different this year at the American Psychiatric Association meeting was that the neuroscientists decided to show up."
"But this year, there were over two dozen talks on neuromodulation! In years past, the leading lights of brain stimulation and cutting-edge brain imaging weren't invited to speak; this year, they were."
"At the exhibition hall, it wasn't just traditional drugs this time. There was more and more neurotechnology that made me feel like the future was bright. And that's just the stuff they were ready to show off. In after-hours conversations, I heard about even more mind-blowing technology on the way."
"There are several FDA-cleared take-home brain stimulation devices (Flow for depression, Neuralief"
Read at Psychology Today
Unable to calculate read time
Collection
[
|
...
]